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A B S T R A C T
Background
Cough is the most common symptom presenting to primary healthcare services. Cough in children is associated with significant
morbidity for both children and their parents. While inhaled corticosteroids (ICS) can potentially reduce cough associated with airway
inflammation and airway hyper-reactivity, use of ICS in children is not without potential adverse effects. Therefore, it would be
beneficial to clinical practice to evaluate the evidence for the efficacy of ICS in reducing the severity of cough in children with subacute
cough (defined as cough duration of two to four weeks) systematically.
Objectives
To evaluate the efficacy of ICS in reducing the severity of cough in children with subacute cough.
Search methods
The Cochrane Register of Controlled Trials (CENTRAL), the Cochrane Airways Group Specialised Register, MEDLINE, EMBASE,
review articles and reference lists of relevant articles were searched. The latest searches were performed in November 2011.
Selection criteria
All randomised controlled trials (RCTs) comparing ICS with a control group in children with subacute cough were considered for
inclusion.
Data collection and analysis
Search results were reviewed against pre-determined criteria for inclusion. Two sets of review authors independently selected, extracted
and assessed the data for inclusion. Study authors were contacted for further information where required. Data were analysed as
’intention to treat’.
1Inhaled corticosteroids for subacute cough in children (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
The search identified 1178 potentially relevant titles; however, there were no published studies that were specifically designed to answer
this question. Two studies met criteria for inclusion in the review and 98 children were included in the meta-analysis. There was no
significant difference between groups in the proportion of children ’not cured’ at follow-up (primary outcome measure), with a pooled
odds ratio (OR) of 0.61 (95% confidence interval (CI) 0.24 to 1.55). However, the included studies were limited in their ability to
answer the review question by the fact that all participants were infants, post acute bronchiolitis illness, and cough duration at the start
of study medication was ill-defined.
Authors’ conclusions
There is currently no evidence to support the use of ICS for treatment of subacute cough in children. However, this systematic review
is limited by the small number of studies available for analysis and the size, quality and design of these studies. Further well-designed
RCTs are required to support or refute the efficacy of treatment with ICS in children with subacute cough.
P L A I N L A N G U A G E S U M M A R Y
Inhaled corticosteroids for subacute cough in children
Cough is the most common symptom presenting to doctors. Cough in children negatively impacts on both children and their families,
therefore any improvement would be beneficial. Treatment with inhaled corticosteroids may reduce the severity of subacute cough
(coughing for two to four weeks) in children by reducing airway inflammation. Data from two small studies were available for inclusion
in this review; however, both studies were in infants following hospitalisation for an acute bronchiolitis illness (98 infants in total).
There was no difference between groups in the proportion of children ’not cured’ at follow-up. There were no significant side effects in
either of these studies. Without further available evidence, recommendations for the use of inhaled corticosteroids for the treatment of
subacute cough in children cannot be made. Further well-designed studies, including children over 12 months of age, are required to
determine whether treatment with inhaled corticosteroids can safely and effectively reduce the severity of subacute cough in children.
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B A C K G R O U N D
Cough is the most common symptom presenting to primary
healthcare services in Australia (Britt 2009) and worldwide
(Cherry 2008; Irwin 2006a). The symptom of cough is also one
of the most frequent reasons for referrals to paediatricians and
respiratory physicians (Chang 2006a). In the US, the number of
doctor visits per year for cough exceeds 27 million (Cherry 2008).
Cough accounts for 6.8 of every 100 visits to general practitioners
in Australia (Britt 2009). Cough in children is not only a common
problem, but one that impacts at both an individual level with
reduced quality of life (Marchant 2008), as well as at a population
level due to the considerable expense of treatment (Irwin 2006a).
Irrespective of the aetiology or cough duration, the symptom of
cough in children is associated with significant morbidity to par-
ents (Cornford 1993; Fuller 1998) and children as it disrupts usual
daily activities including school and sleep (Faniran 1998). Cough
was the most common reason for school absenteeism in a large
community-based study in the UK (Doull 1996). In the US, one
in 10 children receivesmedication for their acute cough at any one
time (Vernacchio 2008). This reflects the anxiety and distress to
parents caused by the symptom of cough in their child (Cornford
1993). In addition, the use of unnecessary or inappropriate med-
ications for cough is associated with adverse effects (Thomson
2002).
Description of the condition
Cough duration is variably defined. In the Australian and US,
paediatric cough guidelines, subacute cough is defined as cough
present for two to four weeks (Chang 2006a; Chang 2006b). Acute
cough in children is defined as cough duration of less than two
weeks, with chronic cough defined as cough duration of longer
than four weeks (Chang 2006a). The paediatric definitions are
different to the adult definitions (with chronic cough defined as
cough lasting longer than eightweeks), due to the natural history of
acute upper respiratory tract infections in children (Hay 2002) and
the knowledge that cough in children differs from cough in adults
(Chang 2006b; Chang 2005). Cough related to an acute upper
respiratory tract infection resolves within one to three weeks in
most pre-school aged childrenpresenting to primary care; however,
this cough persists for up to three weeks following an acute upper
respiratory tract infection in 10% of young children (Hay 2002).
Description of the intervention
Corticosteroids are a commonly used medication for eosinophilic
dominated airway diseases such as asthma. For asthma, oral corti-
costeroids are used predominantly duringperiods of exacerbations,
while inhaled corticosteroids (ICS) are used mainly for mainte-
nance or preventive therapy (BTS SIGN 2012). In children, ICS
can be delivered via a metered dose inhaler (MDI) with or without
a spacer, dry powder inhalation (DPI) or through nebulisation.
How the intervention might work
Short-term treatment with ICS reduces cough frequency in adults
with post-infectious cough (Gillissen 2007). Cough is the domi-
nant symptom of airway inflammation, and airway hyper-reactiv-
ity is also associated with cough (Nair 2010). ICS can ameliorate
airway inflammation and airway hyper-reactivity (at least in some
people) (Rytila 2008), thus ICS treatment can potentially reduce
the severity of cough in children with sub-acute cough.
Why it is important to do this review
ICS is recommended as an empirical treatment in guidelines on
adults with chronic cough (Irwin 2006b). Although ICS is not
recommended in children with isolated chronic cough (i.e. cough
without any other symptoms) (Chang 2006b), many doctors con-
tinue to use ICS in children with cough of various durations. Ev-
idence examining the use of ICS for non-specific chronic cough
in children has been addressed in a Cochrane systematic review
(Tomerak 2005) and an examination of the use of ICS for acute
cough is embedded within another Cochrane review in prepa-
ration. Although physicians often think “it’s only a cough”, the
symptom of cough is burdensome and substantially reduces the
quality of life of parents (Marchant 2008). Due to the significant
impact of cough in children, improvement from ICS treatment
and other therapies would be beneficial. However, as with all in-
terventions, adverse events also need to be considered. Given the
knowledge that high-dose ICS treatment is associated with signif-
icant adverse effects in children, this is a particularly important
consideration in this review. A systematic review of the benefits (or
otherwise) of ICS on subacute cough would therefore be useful to
help guide clinical practice.
O B J E C T I V E S
To evaluate the efficacy of ICS in reducing the severity of cough
in children with subacute cough (cough duration of two to four
weeks).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) comparing ICS with a
control group in children with subacute cough.
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Types of participants
Children (under 18 years of age) with subacute cough (cough
duration of two to four weeks).
Exclusion criteria: participants with known chronic respiratory
disease (such as cystic fibrosis, asthma, bronchiectasis, aspiration
lung disease). Children with cough post acute respiratory infec-
tions such as croup were not excluded.
Types of interventions
All randomised controlled comparisons of any type of ICS (MDI,
DPI or nebulised). Trials comparing two or more medications
without a placebo comparison group were not included. Trials that
included the use of other medications or interventions were only
to be included if all participants had equal access to such medi-
cations or interventions. Treatment with ICS had to be inclusive
of the subacute cough phase (two to four weeks) but could have
commenced during the first two weeks of illness and continued
beyond the four-week mark.
Types of outcome measures
Reporting of one ormore outcomes of interestwas not an inclusion
criterion.
Primary outcomes
Attempts were made to obtain data on at least one of the following
outcome measures:
Primary outcome:
1. Proportion of participants who were not cured or not
substantially improved (> 70% reduction in cough severity
measure) at follow-up (clinical failure).
The following hierarchy of assessment measures for cough severity
was to be used (i.e. where two or more assessment measures are
reported in the same study, the outcome measure that is listed first
in the hierarchy was to be used):
1. objective measurements of cough indices (cough frequency,
cough receptor sensitivity);
2. symptomatic (quality of life, Likert scale, visual analogue
scale, level of interference of cough, cough diary) - assessed by
the patient (child);
3. symptomatic (quality of life, Likert scale, visual analogue
scale, level of interference of cough, cough diary) - assessed by
the parents/carers;
4. symptomatic (Likert scale, visual analogue scale, level of
interference of cough, cough diary) - assessed by clinicians.
Secondary outcomes
1. Proportion of participants who were not cured at follow-up.
2. Proportion of participants who were not substantially
improved at follow-up.
3. Mean difference in cough indices (cough diary, cough
frequency, cough scores, quality of life).
4. Proportion of participants experiencing adverse effects of
the intervention.
5. Proportion of participants experiencing complications (e.g.
requirement for medication change).
The same hierarchy of assessment measures for cough severity was
to be used for secondary outcomes one and two.
Search methods for identification of studies
Electronic searches
RCTs were identified using the Cochrane Airways Group Spe-
cialised Register of trials, which is derived from systematic searches
of bibliographic databases including the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED and PsycINFO, and handsearching of respi-
ratory journals and meeting abstracts (please see the Airways
Group Module on The Cochrane Library for further details). Ad-
ditional searches of CENTRAL, MEDLINE and EMBASE were
also conducted. The full search strategies are detailed in Appendix
1. Databases were searched from their inception up to November
2011, and there was no restriction on the language of publication.
Searching other resources
We handsearched references from identified papers and reviews
for further references. We contacted authors to request their iden-
tification of any unpublished or missed trials.
Data collection and analysis
Selection of studies
Two sets of review authors (SA, AC for initial search; SA, JM
for subsequent search) independently assessed for inclusion all
the potentially relevant studies identified as a result of the search
strategy. It was planned that any disagreement would be resolved
through discussion or, if required, adjudication by a third review
author.
Data extraction and management
Trials that satisfied the inclusion criteria were independently re-
viewed and the following information recorded: study setting, year
of study, source of funding, participant recruitment details (in-
cluding number of eligible people), inclusion and exclusion crite-
ria, other symptoms, randomisation and allocation concealment
method, number of participants randomised, blinding (masking)
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of participants, care providers and outcome assessors, duration
of intervention, co-interventions, number of participants not fol-
lowed up, reasons for withdrawals from study protocol (clinical,
side effects, refusal and other), details on side effects of therapy,
and whether intention-to-treat analyses were possible. Data were
extracted for the outcomes described above and any follow-up
data provided in the following four weeks post intervention were
sought. Further information was requested from the study authors
where required.
Assessment of risk of bias in included studies
Two sets of review authors (SA, AC for initial search; SA, JM for
subsequent search) independently assessed risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). It was planned
that any disagreement would be resolved by discussion or by in-
volving a third review author. We assessed the risk of bias accord-
ing to the following domains:
1. allocation sequence generation;
2. concealment of allocation;
3. blinding of participants and investigators;
4. incomplete outcome data;
5. selective outcome reporting.
We also noted other sources of bias. Each potential source of bias
was graded as high risk, low risk or unclear risk, relating to whether
the potential for bias was high, low or unknown, respectively.
Measures of treatment effect
An initial qualitative comparison of all the individually analysed
studies examined whether pooling of results (meta-analysis) was
reasonable. This took into account differences in study popula-
tions, inclusion and exclusion criteria, interventions and outcome
assessment. The results from studies that met the inclusion criteria
and reported any of the outcomes of interest were included in the
subsequent meta-analyses.
For the dichotomous outcome variables of each individual study,
we calculated the odds ratio (OR) and 95% confidence intervals
(CIs) using amodified intention-to-treat analysis (modified if there
were missing values due to drop-outs). We used the Cochrane
statistical package Review Manager 5 (RevMan 2011). Numbers
needed to treat for an additional beneficial effect (NNTB) were
to be calculated from the pooled OR and its 95% CI applied to
a specified baseline risk (from the control group) using an online
calculator (Cates 2003).
For continuous outcomes we planned to calculate the mean dif-
ference and 95% CIs using RevMan 2011. If studies reported out-
comes using different measurement scales, the standardised mean
difference was to be estimated.
Unit of analysis issues
Cross-over trials are not appropriate for this intervention duration
and thus were not included in any meta-analysis but were to be
described in the text.
Dealing with missing data
We contacted investigators or study sponsors in order to verify key
study characteristics and obtain missing numerical outcome data
where possible.
Assessment of heterogeneity
We used the I2 statistic to measure heterogeneity among the trials
in each analysis. If we had identified substantial heterogeneity, we
planned to explore it by using pre-specified subgroup analysis. We
described any heterogeneity between the study results and tested
this to see if it reached statistical significance using the Chi2 test.
We considered heterogeneity to be significant when the P value
was less than 0.10 (Higgins 2011). We categorised heterogeneity
such that a value of under 25% was considered low, around 50%
was considered moderate and over 75% was considered a high
degree of heterogeneity.
Assessment of reporting biases
Where we suspected reporting bias (see ’Selective reporting bias’
below), we attempted to contact study authors asking them to
provide missing outcome data. Where this was not possible, and
themissing datawere thought to introduce serious bias, the impact
of including such studies in the overall assessment of results was
to be explored by a sensitivity analysis.
If combination of data and meta-analysis (with at least five stud-
ies) was possible, we planned to assess publication bias using a
funnel plot. We planned to try and identify and report on any
selective reporting in the included trials, ideally by comparing the
trial protocol with the final published paper, but alternatively by
comparing the ’Methods’ and ’Results’ sections of the published
studies.
Data synthesis
We determined the summary OR and mean differences with their
95% CIs using a fixed-effect model. We planned to use a random-
effects model whenever there were concerns about statistical het-
erogeneity.
Subgroup analysis and investigation of heterogeneity
1. type of control arm (placebo/no treatment);
2. children in different age groups (younger than six years, six
to 14 years and 15 years and above) (as older children are more
likely to have adult-like cough responses);
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3. doses of ICS (low to moderate defined as < 800 µg/day
budesonide equivalent versus high defined as ≥ 800 µg/day
budesonide equivalent).
Sensitivity analysis
Sensitivity analyses were also planned to assess the impact of the
potentially important factors on the overall outcomes:
1. variation in the inclusion criteria;
2. risk of bias in the included studies (i.e. double versus single
blinded or unblinded; allocation clearly concealed versus unclear
or no concealment);
3. analysis using random-effects model;
4. analysis by ’treatment received’ or ’intention-to-treat’
5. nebulised ICS versus MDIs.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The Airways Group register/search identified 1178 potentially rel-
evant titles (see Appendix 1 for search strategy). After assessment
of the abstracts, 14 papers were obtained for consideration for in-
clusion into the review. Two studies were included in the final re-
view (see Figure 1). Both papers were published in English. There
were no RCTs comparing ICS for subacute cough in children over
12 months of age.
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Figure 1. Study flow diagram.
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Included studies
Of the two studies included, one was a single-centre study (Wong
2000) and one was a dual-centre study (Fox 1999). One study
(Wong 2000) received support from a commercial interest (Glax-
oWellcome). Both studies were conducted in hospitals within the
UK and recruited infants admitted to paediatric wards with acute
bronchiolitis, and the studies commenced when the infants were
’ready for discharge’. In both studies, cough duration at com-
mencement of study medication was not specifically defined. The
median age of participants in Fox 1999’s study was 11 weeks.
The mean ages inWong 2000’s study were 3.8 months (treatment
group) and 3.9 months (placebo group). All participants in both
studies were aged under 10.9 months, and the study populations
appeared very similar.
Both studies were double-blind, parallel group RCTs using twice
daily ICS delivered via MDI with spacer and face mask compared
to placebo. One study (Fox 1999) used budesonide 200 µg or
one puff twice daily for eight weeks, and one study (Wong 2000)
used fluticasone propionate 150 µg (3 puffs of a 50 µg inhaler)
twice daily for three months, which are considered comparable
ICS doses. As both these studies incorporate use of ICS beyond
the acute two-week period (i.e. within the subacute definition of
cough), both fulfilled the eligibility criteria of this review.
Outcomes were available at three weeks (Wong 2000) and four
weeks (Fox 1999). An objective outcome measurement of cough
indices (overnight cough recording using a voice-activated tape
recorder) was used in one study (Wong 2000); however, as these
were overnight cough recordings only, there were no objective day-
time cough symptom data available. In the same study (Wong
2000), additional symptomatic cough data (parent-recorded di-
ary card) was only available at three months, therefore this out-
come could not be included in this review.Nodifferentiated cough
symptom data were available in one study (Fox 1999), which
also used parent-recorded respiratory symptom cards (combin-
ing cough and wheeze) as a subjective outcome measure. Only
episodes of cough and wheeze that required treatment by a general
practitioner (GP) or emergency department were included in the
statistical analysis by Fox 1999.
Excluded studies
Twelve papers were excluded as they did not fulfil the criteria for
the review. The main reasons studies were excluded were cough
duration (chronic cough rather than subacute cough) and age
of participants (adults rather than children), see Characteristics
of excluded studies. Other reasons included physician-diagnosed
asthma, non-randomised studies, cross-over study design and non-
ICS treatment.
Risk of bias in included studies
This is summarised in the ’Risk of bias’ summary (Figure 2).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Allocation was unclear in both included studies. Although both
included studies stated that they were randomised, the methods
of sequence generation and allocation concealment were not de-
scribed in either paper.
Blinding
Blinding was unclear in both included studies. Although both
included studies stated they were double blind, the methods used
for blinding were not described in either paper. We could not
determine who collected data in either study or how they were
blinded.
Incomplete outcome data
The total number of participants withdrawn and lost to follow-
up from both included studies were described. The treatment
allocation for each withdrawal was only reported for one study
(Wong 2000). Participants with no overnight cough data follow-
ing the baseline cough recordings were eliminated from the anal-
ysis (Wong 2000).
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Selective reporting
Limitations of both studies were discussed by the authors. There
was no suggestion that selective reporting had occurred.
Other potential sources of bias
The number of potentially eligible participants was not described
in either study, resulting in an unclear assessment of recruitment
selection bias.
Both studies included participants within a distinct patient pop-
ulation with a small age range. Participants were not specifically
recruited for cough, cough duration at commencement of study
medication was ill-defined, and studies include limited objective
cough measures.
Effects of interventions
See: Summary of findings for the main comparison Inhaled
corticosteroids for subacute cough
The two studies included 104 infants. Both studies used twice
daily ICS treatment via MDI, spacer and face mask. Outcomes
for the two studies were available at three weeks (Wong 2000) and
four weeks (Fox 1999). Follow-up data at these time points were
available for 98 infants.
Primary outcome
Ourprimary outcomewas the proportionof participantswhowere
not cured or substantially improved (> 70% reduction in cough
severity measure) at follow-up (clinical failure).
Data from 98 infants in both studies were combined for this out-
come measure. The number of children not cured at follow-up
was 36, using an ’intention-to-treat’ analysis. The control event
rate was 69.57% (Wong 2000) and 17.86% (Fox 1999) in the
two studies. There was no significant difference between groups in
the proportion of children ’not cured’ at follow-up, with a pooled
OR of 0.61 (95% CI 0.24 to 1.55), see Figure 3 and Summary of
findings for the main comparison.
Figure 3. Forest plot of comparison: 1 Inhaled corticosteroids versus placebo, outcome: 1.1 Clinical failure.
Both included studies used a placebo control, thus subgroup anal-
ysis of type of control arm could not be performed. All participants
were infants aged less than 12 months, therefore subgroup anal-
ysis of children in different age groups could not be performed.
Both included studies used a low-to-moderate dose of ICS, hence
subgroup analysis of doses of ICS could not be performed.
Secondary outcomes
Proportion of participants who were not cured at follow-up was
the same as the primary outcome measure as there were no data
available for the proportion of participants who were not substan-
tially improved at follow-up in either study. There were no avail-
able data to suggest the severity of ongoing symptoms. Follow-up
data for both studies, at three weeks (Wong 2000) and four weeks
(Fox 1999), were presented as ’cured’ versus ’not cured’.
Mean difference in cough indices (cough diary, cough frequency,
cough scores, quality of life): in the Wong 2000 study, cough
recordings at the different time points were reported as group
median values of weightedmean changes frombaseline, hence data
could not be entered into a forest plot. Authors of the study (Wong
2000) reported improvements in both groups but no significant
difference between the ICS and placebo groups; at three weeks,
the change in cough events per hour were -0.12 (95% CI -0.69
to 0) in the ICS group and -0.27 (95% CI -0.44 to -0.01) in
the placebo group, and at six weeks, the respective values were -
0.57 (95% CI -2.05 to -0.04) and -0.76 (95% CI -1.64 to -0.15).
Symptomatic cough data (parent-recorded diary card) in the study
byWong 2000 were only available at threemonths, therefore could
not be included in this review. No differentiated cough symptom
data were available in the study by Fox 1999, which also used
parent-recorded respiratory symptomcards (combining cough and
wheeze) as a subjective outcome measure.
Proportion of participants experiencing adverse effects of the in-
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tervention: Wong 2000 reported that two infants in the flutica-
sone treatment group developed oral candidiasis during follow-
up; however, no fungal infections occurred during the treatment
period. Fox 1999 reported two adverse events; however, these were
unrelated to the study treatment (one infant in the placebo group
was admitted to hospital with viral gastroenteritis and one infant
in the budesonide group was re-admitted with mild coughing and
wheezing).
Proportion of participants experiencing complications (e.g. re-
quirement for medication change): there were no reported com-
plications in either study.
Sensitivity analyses
As there were only two studies included in this review, re-analysis
using a random-effects model or by ’treatment received’ or ’inten-
tion-to-treat’ was not possible.
Inclusion criteria were similar in both studies, therefore re-analysis
by variation in the inclusion criteria could not be performed.
Risk of biases in the included studies (i.e. double versus single
blinded or unblinded; allocation clearly concealed versus unclear
or no concealment) was considered to be similar between the two
available studies, as both studies were double blinded; however,
allocation concealment was not described in either study.
Both studies used MDIs, therefore sensitivity analysis comparing
nebulised ICS versus MDIs was unable to be performed.
D I S C U S S I O N
Summary of main results
A total of 98 infants were included in the meta-analysis. There
was no significant difference between groups in the proportion of
children ’not cured’ (primary outcome measure), see Summary of
findings for the main comparison. There is currently no evidence
to support the use of ICS in subacute cough in children. The
evidence is limited by the small number of studies available for
analysis as well as the quality and design of included studies.
Overall completeness and applicability of
evidence
Evidence is limited by the small number of studies eligible for in-
clusion in this review. The two included studies both recruited a
distinct patient population with a small age range, as all partici-
pants were less than 12 months of age. Further, while it is clear
that treatment with ICS was administered in the non-acute phase,
it is unclear exactly when the intervention was commenced. It also
remains unknown if ICS commenced early (i.e. during the acute
phase) prevents ongoing symptoms, and differs from later use of
ICS for treatment of cough.
All participants were infants recruited post hospitalisation for an
acute bronchiolitis illness, so are a select subgroup of the general
paediatric population. Studies have shown that infants with bron-
chiolitis have increased likelihood of ongoing recurrent episodes
of cough and wheeze in the following 12 to 24 months, suggest-
ing some ongoing airway pathology post this illness (Wennergren
2001). Studies on the use of ICS in subacute cough, limited to
this distinct patient population, that is post acute bronchiolitis, are
likely to be biased and not applicable to the paediatric population
as a whole.
Both of these studies did not specifically recruit for the symptom
of cough, did not have a clearly defined cough duration at the start
of study treatment and included limited objective coughmeasures.
In terms of cough indices, Fox 1999 did not differentiate cough
symptom data and Wong 2000 measured overnight cough only.
While outcomes for both studies were available in the short term,
both studies were designed as longer-term interventions with a
longer follow-up period, limiting completeness and applicability
when assessing only for shorter-term outcomes.
Further, clinicians should be cognisant that cough is a symptom
and not a disease, and that use of ICS is not without potential
adverse events. Both included studies were small and short term
thus unlikely to define important yet uncommon adverse events
associated with ICS such as growth failure and adrenal suppression
(Patel 2001).
Quality of the evidence
Both included studies were double-blind RCTs; however, neither
the sequence generation or allocation concealment methods were
adequately described in either study, therefore the quality of the
included studies is unclear. Cough recordings reported by Wong
2000 were overnight recordings only, with no objective day-time
cough data available, and available data were only presented as
’cured’ versus ’not-cured’, which are both potential weaknesses of
this study. No differentiated cough symptom data were available
in the study by Fox 1999, which was confirmed via written corre-
spondence with the study investigator. In addition, the difference
in control event rates between the two included studies (69.57%
in Wong 2000 compared to 17.86% in Fox 1999) suggests that
there may have been differences between the two included study
populations, despite the apparent similarities.
Potential biases in the review process
There were no perceived biases in the review process.
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Agreements and disagreements with other
studies or reviews
There are no known other reviews or studies available for compar-
ison.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Due to the significant impact of cough in children, improvement
from ICS treatment or other therapies would be beneficial. With-
out further available evidence, recommendations for the use of ICS
for the treatment of subacute cough in children cannot be made.
This review is limited by the small number of studies available
for inclusion, the characteristics of the included studies, and the
data available for analysis. The two studies included in this review
describe a small number of participants from a distinct patient
population within a small age range. The quality of the included
studies was limited by the unclear risk of allocation concealment
biases.
Implications for research
Further well-designed double-blind parallel RCTs, specifically
powered to answer this question, and using appropriate randomi-
sation sequence generation and allocation concealment are re-
quired to support or refute the efficacy of treatment with ICS in
children with subacute cough, and make valid conclusions in re-
spect to the safety of this treatment. These studies should include
children over 12 months, without acute bronchiolitis and with
clearly defined cough duration at commencement of study treat-
ment, to assess the role of ICS treatment in children with suba-
cute cough. Future RCTs should be designed to include objective
cough outcome measures such as cough frequency recordings, or
validated symptomatic measures such as a cough score diary or
visual analogue scale as assessed by the child, if age permits, and
the parent/guardian. The study design should include a clear and
appropriate definition of clinical improvement, utilising these ob-
jective measures.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Fox 1999
Methods Dual-centre double-blind randomised controlled trial comparing budesonide 200 µg or
1 puff twice daily (via metered dose inhaler (MDI) with modified spacer and mask)
versus placebo in infants admitted to hospital with acute bronchiolitis
At baseline participants had a medical history, nasopharyngeal swab and clinical exami-
nation performed
Randomisation occurred when infants were considered ready for discharge. Method of
sequence generation and allocation concealment not described
Participants 60 infants, aged median (range) 11 (1 to 42) weeks, with clinical diagnosis of acute
viral bronchiolitis requiring hospital admission were included. There were no significant
differences in any patient characteristics between the 2 groups
Inclusion criteria: infants aged less than 12 completed months with a clinical diagnosis
of acute viral bronchiolitis
Exclusion criteria: children with underlying cardiopulmonary disease, including congen-
ital heart disease, bronchopulmonary disease and cystic fibrosis, and those who experi-
enced respiratory problems in the neonatal period, or required mechanical ventilation
during current illness
Follow-up data at 1 month were available for 54 of the 60 infants initially randomised.
Budesonide group N = 26 (20 males), placebo group N = 28 (14 males)
1 participant was excluded after randomisation but before receiving any studymedication
as required mechanical ventilation, 1 participant was excluded at the first follow-up
appointment due to poor compliance, and 4 additional participants failed to attend any
follow-up appointments
8 included infants had been born prematurely between 32 and 37 weeks’ gestation, with
6 randomised to the placebo group; however, the difference between groups was non-
significant
Interventions Treatment group received inhaled budesonide 200 µg or 1 puff twice daily (via MDI
with spacer and mask) for 8 weeks, versus placebo control group
Additional medications received by participants during the next 12-month follow-up
period included cough suppressants, oral and inhaled bronchodilators, and inhaled and
systemic corticosteroids
Outcomes Primary outcome: reduction in incidence of coughing and wheezing episodes requiring
treatment by a general practitioner (GP) or emergency department during a 12-month
follow-up period
Parent-completed diary card record of respiratory symptoms (episodes of coughing and
wheezing), GP and hospital visits, and medication prescribed and used over a 12-month
follow-up period
Clinical examinations occurred at 1, 2, 6 and 12 months post discharge
2 adverse events were recorded; however, these were unrelated to study medication. 1
infant was admitted to hospital with viral gastroenteritis and 1 infant was re-admitted
with mild coughing and wheezing
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Fox 1999 (Continued)
Notes Only episodes of cough and wheeze that required treatment by a GP or emergency
department were included in the statistical analysis
Written communication with the author did not provide further differentiated cough
symptom data
Study funded by grants from the National Asthma Campaign and The St Thomas’s
Hospital Special Trustees
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised to receive either budesonide
or placebo (30 to each group). Method of
sequence generation not described
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who was the assessor
Incomplete outcome data (attrition bias)
All outcomes
High risk Reasons for withdrawals and missing data
described; however, not included in final
analysis
Selective reporting (reporting bias) Low risk Limitations of study discussed. Authors
suggested possible Type 1 error due tomore
males in the treatment group
Other bias Unclear risk Possible selection bias in recruitment, as
number of potentially eligible participants
not described. Additional medications al-
lowed during the follow-up period in-
cluded inhaled and systemic corticosteroids
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Wong 2000
Methods Single-centre, double-blind randomised controlled trial comparing fluticasone propi-
onate 150 µg (3 puffs of a 50 µg inhaler) twice daily (via metered dose inhaler (MDI)
with low volume spacer and mask) versus placebo, in infants admitted to hospital for
first documented episode of acute bronchiolitis
Nasopharyngeal aspirates were sent for immunofluorescent study and viral culture. A
detailed history was obtained and documentedwith examination findings and treatments
Randomisation occurred when infants were considered ready for discharge. Method of
sequence generation and allocation concealment not described
Statistical analysis was performed on an intention-to-treat basis
Participants 48 infants aged 2 to 52 weeks, with first documented episode of acute bronchiolitis
requiring admission
Inclusion criteria: infants admitted with first episode of lower respiratory tract infection,
diagnosed by 1 investigator as having acute bronchiolitis using COURT criteria. Specific
inclusion ages not stated
Exclusion criteria: birth before 36 weeks’ gestation; congenital heart disease or syndromic
abnormalities; established systemic or chronic illnesses; treatment with corticosteroids
or mechanical ventilation before entering the study. Those who were unable to master
the required medication delivery technique after education were also excluded
Follow-up data at 3 weeks were available for 44 of the 48 infants initially randomised.
Fluticasone propionate group N = 21, placebo group N = 23. The demographic data
were similar in the 2 groups
2 participants in the treatment group were withdrawn due to distress resulting from the
application of the face mask, with a third participant withdrawn due to social reasons. 1
participant in the placebo group was withdrawn for non-compliance after the treatment
period
Interventions Treatment group received 150 µg fluticasone propionate via MDI with low-volume
spacer and mask for 3 months, versus placebo control group
Prescription of additional medications by independent doctors included beta2-agonists,
corticosteroids and antibiotics
Outcomes Primary outcome: reduction in overnight cough rate from pre-treatment baseline levels
Overnight cough recordings using a voice-activated tape recorder, attempted at baseline
and at each of the 6 follow-up visits. During the treatment period, 87% of attempted
cough recordings were technically successful. Not attempted on 10 occasions. Weighted
mean change in cough rate was used to compare reductions in cough rate between
treatment groups
Percentages of infants cough free (based on overnight recording) at each home visit were
reported
Overnight oxygen saturationmeasurements were also conducted at time of cough record-
ing
Data on symptom frequency, use of rescue respiratory medications, hospital admissions
was collected. Follow-up clinical examinations occurred on 6 occasions over 12 months.
Clinical decisions about need for additional treatments weremade by family practitioners
and hospital doctors. Family doctor and hospital records were examined at the end of
the study for collaborative information
Parents completed symptom diaries scoring cough, wheeze and general well-being for
both day and night; however, data were reported as percentage of days over 3 months
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Wong 2000 (Continued)
for each symptom score
Lung function was measured 6 months after hospital discharge (3 months after the
treatment period), therefore could not be included in this review
Notes Written communication with the study author did not provide further differentiated
cough symptom data
Project funded by GlaxoWellcome
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as
randomised; however, method of sequence
generation not described
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not de-
scribed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Stated double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Primary outcomemeasure overnight cough
rate (objective measure); however, unclear
who was the assessor
Incomplete outcome data (attrition bias)
All outcomes
High risk Drop-outs and withdrawals described, and
included in final analysis up until with-
drawal date. Participants with no overnight
cough data following the baseline cough
recordings were eliminated from the anal-
ysis
Selective reporting (reporting bias) Low risk Limitations of study discussed
Other bias Unclear risk Possible selection bias in recruitment, as
number of potentially eligible partici-
pants not described. Prescription of addi-
tional medications by independent doctors
included bronchodilators, corticosteroids
and antibiotics.More infants in the placebo
group received bronchodilators/corticos-
teroids, but not antibiotics
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Davies 1999 Double-blind randomised controlled trial of inhaled fluticasone propionate versus placebo. Cough duration
was≥ 6 weeks, although inclusion criteria was > 3 weeks. Excluded from review as chronic cough, not subacute
cough
Evald 1989 Randomised controlled trial of inhaled beclomethasone dipropionate versus placebo. Cross-over occurred at 2
weeks. Excluded from review as chronic cough, not subacute cough, cross-over study design, and participants
were adults, not children
Jartti 2007 Randomised controlled trial of oral prednisolone versus placebo. Excluded from review as oral prednisolone,
not inhaled corticosteroids, and investigating effect on wheezing in virus-positive children, not cough
Kooi 2008 Double-blind randomised controlled trial of inhaled fluticasone propionate, montelukast or placebo in children
with asthma-like symptoms. Study inclusion criteria does not comply as no separate cough symptom data,
and daily symptoms were not required for inclusion. Run-in period of 2 weeks implemented. Excluded from
review as chronic cough, not subacute cough
Kwon 2006 Not a randomised controlled trial (RCT). Study of adults with cough duration of 3 to 8 weeks who underwent
bronchoprovocation and induced sputum tests to determine treatment with inhaled corticosteroids. Excluded
from review as not an RCT, subacute and chronic cough, and adults, not children
Moskovljevic 2009 Double-blind randomised controlled trial of inhaled fluticasone propionate, montelukast or placebo in children
aged 8 to 18. Excluded from review as study inclusion criteria do not comply, as participants had asthma-like
symptoms, and no short-term data were available (collected at baseline and after 3 months)
Pelkonen 2009 Randomised controlled trial of inhaled budesonide or placebo in children aged 3 to 26 months with abnormal
lung function. Lower range of cough duration was 2 months, therefore excluded from review as chronic cough,
not subacute cough, and abnormal lung function suggesting underlying condition
Ponsioen 2005 Double-blind randomised controlled trial of inhaled fluticasone propionate versus placebo in adults with cough
duration ≥ 2 weeks. Excluded as adult participants, not children
Pornsuriyasak 2005 Double-blind randomised controlled trial of inhaled budesonide or placebo in participants with persistent post
upper respiratory tract infection cough. All participants were aged≥ 18 years, although inclusion criteria was >
15 years (as per written communication with author). Excluded from review as adult participants, not children
Profita 2010 Double-bind randomised controlled trialof inhaled beclomethasone dipropionate versus placebo in children
with clinical diagnosis of intermittent asthma. Excluded from review as study inclusion criteria does not comply
as participants had asthma
Puhakka 1998 Double-blind randomised controlled trial of intranasal fluticasone propionate versus placebo in adults for
common cold. Excluded from review as adults, not children, and intranasal not inhaled corticosteroids, cough
symptom data not differentiated
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(Continued)
Ribeiro 2007 Double-blind randomised controlled trial of inhaled beclomethasone dipropionate versus placebo in adults
with chronic cough (duration of ≥ 8 weeks). Excluded from review as chronic cough, not subacute cough and
adults, not children
Rytila 2000 Single-blind randomised controlled trial of inhaled beclomethasone dipropionate versus placebo in adults with
asthma. Excluded from review as adults, not children, and participants with asthma
Yuksel 1992 Double-blind randomised controlled trial of inhaled beclomethasone dipropionate versus placebo in premature
infants. Cough duration was greater than 4 weeks. Excluded from review as chronic cough, not subacute
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D A T A A N D A N A L Y S E S
Comparison 1. Inhaled corticosteroids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure 2 98 Odds Ratio (M-H, Fixed, 95% CI) 0.61 [0.24, 1.55]
Analysis 1.1. Comparison 1 Inhaled corticosteroids versus placebo, Outcome 1 Clinical failure.
Review: Inhaled corticosteroids for subacute cough in children
Comparison: 1 Inhaled corticosteroids versus placebo
Outcome: 1 Clinical failure
Study or subgroup
Inhaled
corticos-
teroids Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fox 1999 4/26 5/28 35.9 % 0.84 [ 0.20, 3.53 ]
Wong 2000 11/21 16/23 64.1 % 0.48 [ 0.14, 1.65 ]
Total (95% CI) 47 51 100.0 % 0.61 [ 0.24, 1.55 ]
Total events: 15 (Inhaled corticosteroids), 21 (Placebo)
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ICS Favours placebo
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A P P E N D I C E S
Appendix 1. Database search strategies
Airways Group Register
#45=COUGH and (((steroid* or corticosteroid* or glucocorticosteroid* or glucocorticoid* or corticoid*) AND (inhal*)) or (be-
clomethasone or budesonide or fluticasone or ciclesonide or mometasone or flunisolide or mometasone))
CENTRAL (on The Cochrane Library)
#1 MeSH descriptor Cough explode all trees
#2 cough*
#3 (#1 OR #2)
#4 MeSH descriptor Adrenal Cortex Hormones explode all trees
#5 (steroid* or corticosteroid* or glucocorticosteroid* or glucocorticoid* or corticoid*) AND (inhal*)
#6 beclomethasone or budesonide or fluticasone or ciclesonide or mometasone or flunisolide or mometasone
#7 (#4 OR #5 OR #6)
#8 (#3 AND #7)
#9 paediatric* or paediatric* or child* or adolescen* or infant* or young* or preschool* or pre-school* or newborn* or new-born* or
neonat* or neo-nat*
#10 MeSH descriptor Child explode all trees
#11 MeSH descriptor Pediatrics explode all trees
#12 MeSH descriptor Infant explode all trees
#13 MeSH descriptor Adolescent explode all trees
#14 (#9 OR #10 OR #11 OR #12 OR #13)
#15 (#8 AND #14)
MEDLINE (Ovid)
1. Cough/
2. cough$.mp. 3. 1 or 2
4. exp Adrenal Cortex Hormones/
5. ((steroid$ or corticosteroid$ or glucocorticosteroid$ or glucocorticoid$ or corticoid) adj5 inhal$).mp.
6. (beclomethasone or budesonide or fluticasone or ciclesonide or mometasone or flunisolide or mometasone).mp.
7. 4 or 5 or 6
8. 3 and 7
9. (clinical trial or controlled clinical trial or randomised controlled trial).pt.
10. (randomised or randomised).ab,ti.
11. placebo.ab,ti.
12. dt.fs.
13. randomly.ab,ti.
14. trial.ab,ti.
15. groups.ab,ti.
16. or/9-15
17. Animals/
18. Humans/
19. 17 not (17 and 18)
20. 16 not 19
21. 8 and 20
22. exp Child/
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23. exp Pediatrics/
24. exp infant/
25. exp adolescent/
26. (paediatric$ or paediatric$ or child$ or adolescen$ or infant$ or young$ or preschool$ or pre-school$ or newborn$ or new-born$
or neonat$ or neo-nat$).mp.
27. 22 or 23 or 24 or 25 or 26
28. 21 and 27
EMBASE (Ovid)
1. exp COUGHING/
2. cough$.mp.
3. 1 or 2
4. exp corticosteroid/
5. ((steroid$ or corticosteroid$ or glucocorticosteroid$ or glucocorticoid$ or corticoid$) adj5 inhal$).mp.
6. (beclomethasone or budesonide or fluticasone or ciclesonide or mometasone or flunisolide or mometasone).mp.
7. 4 or 5 or 6
8. 3 and 7
9. Randomized Controlled Trial/
10. Controlled Study/
11. randomisation/
12. Double Blind Procedure/
13. Single Blind Procedure/
14. Clinical Trial/
15. Crossover Procedure/
16. follow up/
17. exp prospective study/
18. or/9-17
19. (clinica$ adj3 trial$).mp.
20. ((singl$ or doubl$ or trebl$ or tripl$) adj5 (mask$ or blind$ or method$)).mp.
21. exp Placebo/
22. placebo$.mp.
23. random$.mp.
24. (latin adj3 square$).mp.
25. exp Comparative Study/
26. ((control$ or prospectiv$ or volunteer$) adj3 (trial$ or method$ or stud$)).mp.
27. (crossover$ or cross-over$).mp.
28. or/19-27
29. 18 or 28
30. exp ANIMAL/
31. Nonhuman/
32. Human/
33. 30 or 31
34. 33 not 32
35. 29 not 34
36. 8 and 35
37. child/
38. exp pediatrics/
39. infant/
40. adolescent/
41. (paediatric$ or paediatric$ or child$ or adolescen$ or infant$ or young$ or preschool$ or pre-school$ or newborn$ or new-born$
or neonat$ or neo-nat$).mp.
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42. 37 or 38 or 39 or 40 or 41
43. 36 and 42
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Risk of bias categories were updated from ’yes’, ’no’ and ’unclear’ to ’high risk’, ’low risk’ and ’unclear risk’.
Review Manager software version changed from 5.0 to 5.1.
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